01 Apr 2019
Bluejay Diagnostics, Inc. and U.S. Navy Enter Co-Operative Research and Development Agreement to Develop Non-Invasive Point-of-Care Tests for Lyme Disease
Acton, MA – April 1, 2019 – Bluejay Diagnostics, Inc. (Bluejay) is pleased to announce a new Cooperative Research & Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC), Silver Spring, Md. The project, which will take place in Maryland, will investigate and develop a non-invasive point-of-care test for Lyme disease with the goal of improving detection of Lyme disease at an early stage.
This collaboration will focus on the study of antigens from various pathogens, and successful identification of the most immunoreactive antigen. This information will then be used to develop a rapid test for the efficient detection of pathogen-antigens in biofluids (such as serum, urine or other biofluids) using Bluejay’s FDA-Cleared platform technology, which combines immunochromatography and laminar flow using proprietary materials and design.
“We are confident this collaboration will allow the Navy and Bluejay to pursue not only the development of Lyme disease tests, but also for other infectious diseases,” said Neil Dey, Chief Executive Officer for Bluejay Diagnostics. “We look forward to working with the Navy on this project.
The two-year agreement between the Navy and Bluejay Diagnostics will be completed in four phases to identify the most pertinent antigen, confirm sensitivity and specificity, generate specific high-efficient antibodies, and provide a proof-of-concept test on the platform technology.
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc. develops, manufactures and markets easy-to-use, point-of-care medical diagnostics tests. The company offers multiple FDA-Cleared non-invasive, affordable products, including the Allereye® Tear Total IgE Test used to aid in the diagnosis of allergic conjunctivitis, and a urine-based HIV-1 screening test and a HIV-1 confirmatory test. Bluejay, headquartered in Acton, Massachusetts, continues to leverage its innovative, proprietary platform to develop new products for underserved diagnostic markets.
Any forward-looking statements are subject to risks and uncertainties. Actual results may differ materially from anticipated results.
Contact: Jeffrey Aidt
Senior Director, Corporate Marketing
Tel: 978 631 4870